Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients
with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety,
the number of infusions temporally associated with AEs, the rate, severity and relationship
of all AEs and the vital sign changes during each infusion will be evaluated.